WeightWatchers isn’t the only company to feel the disruptive power of the weight loss drugs. London-listed but Irish-based ...

Stat: Vinay Prasad's FDA Speech: Praises Staff, Embraces Evidence In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his admiration for agency ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living with hereditary angioedema were interested in trying a new prophylactic ...